| 摘要 |
<p>The use of substituted azetidinone compounds, e. g. ezetimib, for the manufacture of a medicament for treating or preventing sitosterolemia in mammals, reducing plasma or tissue concentration of at least one non-cholesterol sterol, 5alpha-stanol or plasma concentration of at least one compound selected from phytosterols and 5alpha-stanols and mixtures thereof. The medicament may be combined with an effective amount of at least one lipid lowering agent.</p> |
